Nuritas
Category: AI in Healthcare
Nuritas combines artificial intelligence and genomics to discover and unlock natural bioactive peptides with extraordinary health benefits. Nuritas was founded in 2014. The company is led by Dr. Nora Khaldi. Based in Dublin, Ireland (HQ) and New Canaan, Connecticut, USA. Team size: 73. Total funding raised: $150 million. Latest round: Series C. Key investors include M&G Investments, McWin Capital Partners, Grosvenor, ECBF.
- Founded
- 2014
- Headquarters
- Dublin, Ireland (HQ) and New Canaan, Connecticut, USA
- Team size
- 73
- Total funding
- $150 million
Value proposition
Nuritas offers a unique AI-driven platform to discover peptides that enhance the efficacy of products, providing natural and scientifically proven health benefits.
Products and solutions
PeptiStrong, PeptiSleep, PeptiYouth, PeptiProtect, PeptiPump
Unique value
Nuritas uses AI and genomics to rapidly discover bioactive peptides, significantly reducing the time and cost compared to traditional methods.
Target customer
Businesses in the food, beverage, supplements, and cosmetics industries.
Industries served
Functional foods, Dietary supplements, Medical foods, Cosmetics
Technology advantage
The AI platform, Magnifier, allows for the efficient discovery and development of peptides, providing a competitive edge in the biotech industry.
How they differentiate
Nuritas differentiates itself through its AI-driven discovery platform, which accelerates the identification of effective peptides.
Main competitors
APEPTICO, AnaSpec, BCN Peptides
Key partnerships
Givaudan, Nestlé, Mars, L'Oréal, GNC, The Vitamin Shoppe, Sumitomo Corporation
Notable customers
GNC, The Vitamin Shoppe, L'Oréal, Givaudan, Nestlé, Mars, Cellucor
Major milestones
Closed $42M Series C (Dec 2024), PeptiStrong BMJ Nutrition clinical trial, PeptiSleep peer-reviewed in Sleep Medicine: X (Aug 2026), SmartPeptides in 100+ products / 200M+ doses, US office in New Canaan, CT
Growth metrics
Five commercialized peptide ingredients (PeptiStrong, PeptiSleep, PeptiYouth, PeptiProtect, PeptiPump); SmartPeptides in 100+ consumer products worldwide with 200M+ doses served; 56 patents issued.
Market positioning
Nuritas is positioned as a leader in AI-driven peptide discovery for health and nutrition.
Geographic focus
Global, with a focus on expanding in the US and Europe.
Patents and IP
56 patents issued covering peptides discovered via the Magnifier AI platform.
About Dr. Nora Khaldi
Dr. Nora Khaldi is a mathematician and bioinformatician who founded Nuritas in 2014. She has led the company as its CEO, securing significant funding and expanding its operations to North America. Her work focuses on using AI and genomics to discover and unlock natural bioactive peptides for health benefits.
More AI in Healthcare companies
Official website: https://www.nuritas.com/